FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:634-635 February 8, 2007 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Brennan, D. C.

To the Editor: The article by Brennan et al. (Nov. 8 issue),¹ comparing rabbit antithymocyte globulin and basiliximab as induction therapy in patients who received a renal transplant from a deceased donor, states that the patients included in the trial were at high risk for acute rejection. The data provided are insufficient to confirm that the subjects were at high immunologic risk, classically defined as a peak panel-reactive antibody value of more than 50% or a current value of more than 30%, the loss of a previous graft through rejection within 12 months after transplantation, the presence of a donor-specific . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.